Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60
Rahul Kumar, … , Dean G. Tang, Dhyan Chandra
Rahul Kumar, … , Dean G. Tang, Dhyan Chandra
Published June 2, 2022
Citation Information: J Clin Invest. 2022;132(13):e149906. https://doi.org/10.1172/JCI149906.
View: Text | PDF
Research Article Cell biology Oncology

A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60

  • Text
  • PDF
Abstract

Mitochondrial proteostasis, regulated by the mitochondrial unfolded protein response (UPRmt), is crucial for maintenance of cellular functions and survival. Elevated oxidative and proteotoxic stress in mitochondria must be attenuated by the activation of a ubiquitous UPRmt to promote prostate cancer (PCa) growth. Here we show that the 2 key components of the UPRmt, heat shock protein 60 (HSP60, a mitochondrial chaperonin) and caseinolytic protease P (ClpP, a mitochondrial protease), were required for the development of advanced PCa. HSP60 regulated ClpP expression via c-Myc and physically interacted with ClpP to restore mitochondrial functions that promote cancer cell survival. HSP60 maintained the ATP-producing functions of mitochondria, which activated the β-catenin pathway and led to the upregulation of c-Myc. We identified a UPRmt inhibitor that blocked HSP60’s interaction with ClpP and abrogated survival signaling without altering HSP60’s chaperonin function. Disruption of HSP60-ClpP interaction with the UPRmt inhibitor triggered metabolic stress and impeded PCa-promoting signaling. Treatment with the UPRmt inhibitor or genetic ablation of Hsp60 inhibited PCa growth and progression. Together, our findings demonstrate that the HSP60-ClpP–mediated UPRmt is essential for prostate tumorigenesis and the HSP60-ClpP interaction represents a therapeutic vulnerability in PCa.

Authors

Rahul Kumar, Ajay K. Chaudhary, Jordan Woytash, Joseph R. Inigo, Abhiram A. Gokhale, Wiam Bshara, Kristopher Attwood, Jianmin Wang, Joseph A. Spernyak, Eva Rath, Neelu Yadav, Dirk Haller, David W. Goodrich, Dean G. Tang, Dhyan Chandra

×

Figure 9

DCEM1 inhibits oncogenic signaling and PCa tumor growth in vivo.

Options: View larger image (or click on image) Download as PowerPoint
DCEM1 inhibits oncogenic signaling and PCa tumor growth in vivo.
(A and ...
(A and B) 22RV1 cell xenografts were established in each flank of SCID mice and treated with DCEM1 (60 mg/kg body weight, i.p.) twice weekly. Tumors were harvested, photographed (A), and weighed (B) at 30 days, and results are presented in grams. (C) DEVDase activity was analyzed in 22RV1 xenograft tumor tissues following DCEM1 treatment and is represented as fold change compared to vehicle control. (D) 22RV1 xenograft tissues were sectioned and expression of Ki67, c-Myc, EZH2, and AR proteins was analyzed by immunohistochemistry. Scale bar: 50 μm. (E and F) PC-3 cell xenografts were established in each flank of SCID mice and treated with DCEM1 (60 mg/kg body weight, i.p.) twice weekly. Tumors were harvested, photographed (E), and weighed (F) at 35 days and results are presented in grams. (G) DEVDase activity was analyzed in PC-3 xenograft tumor tissue following DCEM1 treatment and is represented as fold change compared to control. (H) PC-3 xenograft tumor tissues were fixed and sections were used for in situ PLA to analyze HSP60-ClpP interactions in tumor tissue samples. Original magnification, x40. (I–L) TKO animals were treated with either vehicle or DCEM1 (60 mg/kg body weight) twice weekly from 10 weeks of age. Animals were sacrificed at 16 weeks of age and the whole genitourinary tract was harvested and weighed (I). Animals were imaged by MRI at 16 weeks of age and sacrificed. Prostate tissues and tumors were harvested, and representative H&E-stained images are shown (J). Scale bar 100 μm. Whole-tissue lysates from vehicle- or DCEM1-treated (60 mg/kg body weight) TKO tumor tissues were prepared and analyzed for HSP60 and ClpP expression (K) and c-Myc and EZH2 expression (L) by Western blotting. Data are mean ± SD. *P < 0.05, by 2-tailed Student’s t test (B, C, and F–I). Actin serves as loading control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts